Christopher Walsh

Christopher Walsh

Ropes & Gray LLP

Contact  |  View Bio  |  RSS

Latest Publications

Share:

Supreme Court to Decide Important False Claims Act Statute of Limitations and Jurisdictional Bar Issues

On July 1, 2014, the Supreme Court granted certiorari in Kellogg Brown & Root Services, Inc., et al. v. United States ex rel. Carter (No. 12-1497), a case involving two issues that have been central to recent False Claims Act...more

7/7/2014 - Attorney-Client Privilege Certiorari Compliance False Claims Act Internal Investigations Kellogg Brown & Root SCOTUS Work-Product Doctrine

Supreme Court Will Decide Deadline for Prospectus Class Actions

Last Monday the Supreme Court decided to hear Public Employees’ Retirement System of Mississippi v. IndyMac MBS, Inc. (No. 13-640) to resolve when investors can rely on pending class actions to litigate claims of false or...more

3/14/2014 - Class Action Disclosure IndyMac Prospectus SCOTUS Securities Act of 1933

Solicitor General Recognizes Conflict, but Recommends that Supreme Court Deny Review of False Claims Act Case Involving Rule 9(b)...

The United States Solicitor General has recommended that the Supreme Court deny certiorari in United States ex rel. Nathan v. Takeda Pharmaceuticals N.A. Inc., et al. (No. 12-1349), a False Claims Act (“FCA”) case involving...more

2/28/2014 - False Claims Act Federal Rules of Civil Procedure Fraud Pleading Standards SCOTUS

Fourth Circuit Affirms Dismissal of False Claims Act Suit Against Pharmaceutical Company, Rejects Theory of Liability Premised...

Last week, the United States Court of Appeals for the Fourth Circuit issued its opinion in United States ex rel. Rostholder, et al. v. Omnicare, Inc., et al. (No. 12-2431), affirming the district court’s dismissal of the...more

2/26/2014 - False Claims Act FDA Healthcare Medicaid Medicare Omnicare Pharmaceutical

Health Services Provider’s Settlement with DOJ Includes Detailed Factual Admissions and Agreement to Cooperate Against...

On January 8, 2014, pharmaceutical provider BioScrip, Inc. (BioScrip) reached a settlement with the Department of Justice (DOJ) to resolve claims under the False Claims Act (FCA) and the Anti-Kickback Statute (AKS), stemming...more

1/20/2014 - Anti-Kickback Statute DOJ False Claims Act Novartis Pharmaceutical Prescription Drugs Settlement

5 Results
|
View per page
Page: of 1